Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study - PubMed (original) (raw)
Comparative Study
Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study
J Craig Longenecker et al. J Am Soc Nephrol. 2002 Jul.
Abstract
Although atherosclerotic cardiovascular disease (ASCVD) risk in end-stage renal disease (ESRD) is 5 to 30 times that of the general population, few data exist comparing ASCVD risk factors among new dialysis patients to the general population. This cross-sectional study of 1041 dialysis patients describes the prevalence of ASCVD risk factors at the beginning of ESRD compared with estimates of ASCVD risk factors in the adult US population derived from the Third National Health and Nutrition Examination (NHANES III). CHOICE Study participants had a high prevalence of diabetes (54%), hypertension (96%), left ventricular hypertrophy by electrocardiogram (EKG) criteria (22%), low physical activity (80%), hypertriglyceridemia (36%), and low HDL cholesterol (33%). CHOICE participants were more likely to be older, black, and male than NHANES III participants. After adjustment for age, race, gender, and ASCVD (defined as myocardial infarction, revascularization procedure, stroke, carotid endarterectomy, and amputation in CHOICE; and as myocardial infarction and stroke in NHANES III), the prevalence of diabetes, hypertension, left ventricular hypertrophy by EKG, low physical activity, low HDL cholesterol, and hypertriglyceridemia were still more common in CHOICE participants. Smoking, obesity, hypercholesterolemia, and high LDL cholesterol, however, were less common in CHOICE than NHANES III participants. The projected 5-yr ASCVD risk based on the Framingham Risk Equation among those older than 40 yr without ASCVD was higher in CHOICE Study participants (13%) than in the NHANES III participants (6%). In summary, many ASCVD risk factors are more prevalent in ESRD than in the general population and may explain some, but probably not all, of the increased ASCVD risk in ESRD.
Similar articles
- Lipoprotein(a) and prevalent cardiovascular disease in a dialysis population: The Choices for Healthy Outcomes in Caring for ESRD (CHOICE) study.
Longenecker JC, Coresh J, Marcovina SM, Powe NR, Levey AS, Giaculli F, Fink NE, Klag MJ. Longenecker JC, et al. Am J Kidney Dis. 2003 Jul;42(1):108-16. doi: 10.1016/s0272-6386(03)00413-x. Am J Kidney Dis. 2003. PMID: 12830462 - High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients.
Longenecker JC, Klag MJ, Marcovina SM, Liu YM, Jaar BG, Powe NR, Fink NE, Levey AS, Coresh J. Longenecker JC, et al. J Am Soc Nephrol. 2005 Jun;16(6):1794-802. doi: 10.1681/ASN.2004110922. Epub 2005 Mar 30. J Am Soc Nephrol. 2005. PMID: 15800123 - Triglyceride-Rich Lipoproteins, Apolipoproteins, and Atherosclerotic Cardiovascular Events Among Patients with Diabetes Mellitus and End-Stage Renal Disease on Hemodialysis.
Lamprea-Montealegre JA, Katz R, Scharnagl H, Silbernagel G, März W, Drechsler C, Wanner C, de Boer IH. Lamprea-Montealegre JA, et al. Am J Cardiol. 2021 Aug 1;152:63-68. doi: 10.1016/j.amjcard.2021.04.023. Epub 2021 Jun 6. Am J Cardiol. 2021. PMID: 34108090 - Treatment of hypertension in renal failure patients: when do we overtreat? When do we undertreat?
Rosansky SJ. Rosansky SJ. Blood Purif. 1996;14(4):315-20. doi: 10.1159/000170279. Blood Purif. 1996. PMID: 8873957 Review. - Cardiovascular disease in dialysis patients.
Cozzolino M, Mangano M, Stucchi A, Ciceri P, Conte F, Galassi A. Cozzolino M, et al. Nephrol Dial Transplant. 2018 Oct 1;33(suppl_3):iii28-iii34. doi: 10.1093/ndt/gfy174. Nephrol Dial Transplant. 2018. PMID: 30281132 Free PMC article. Review.
Cited by
- Trimethylamine N-Oxide and Cardiovascular Events in Hemodialysis Patients.
Shafi T, Powe NR, Meyer TW, Hwang S, Hai X, Melamed ML, Banerjee T, Coresh J, Hostetter TH. Shafi T, et al. J Am Soc Nephrol. 2017 Jan;28(1):321-331. doi: 10.1681/ASN.2016030374. Epub 2016 Jul 19. J Am Soc Nephrol. 2017. PMID: 27436853 Free PMC article. Clinical Trial. - Risk of Stroke in Patients with ESRD.
Masson P, Kelly PJ, Craig JC, Lindley RI, Webster AC. Masson P, et al. Clin J Am Soc Nephrol. 2015 Sep 4;10(9):1585-92. doi: 10.2215/CJN.12001214. Epub 2015 Jul 24. Clin J Am Soc Nephrol. 2015. PMID: 26209158 Free PMC article. - Association of trimethylamine _N_-Oxide with cardiovascular and all-cause mortality in hemodialysis patients.
Zhang P, Zou JZ, Chen J, Tan X, Xiang FF, Shen B, Hu JC, Wang JL, Wang YQ, Yu JB, Nie YX, Chen XH, Yu JW, Zhang Z, Lv WL, Xie YQ, Cao XS, Ding XQ. Zhang P, et al. Ren Fail. 2020 Nov;42(1):1004-1014. doi: 10.1080/0886022X.2020.1822868. Ren Fail. 2020. PMID: 32985309 Free PMC article. - Promotion and support of physical activity in elderly patients on hemodialysis: a case study.
Shiota K, Hashimoto T. Shiota K, et al. J Phys Ther Sci. 2016 Apr;28(4):1378-83. doi: 10.1589/jpts.28.1378. Epub 2016 Apr 28. J Phys Ther Sci. 2016. PMID: 27190487 Free PMC article. - [Clinical issues with uremia].
Girndt M. Girndt M. Internist (Berl). 2012 Jul;53(7):817-22. doi: 10.1007/s00108-011-3013-2. Internist (Berl). 2012. PMID: 22684210 German.
Publication types
MeSH terms
Grants and funding
- K08-HL 03896/HL/NHLBI NIH HHS/United States
- K24-DK 02643/DK/NIDDK NIH HHS/United States
- K24-DK 02856/DK/NIDDK NIH HHS/United States
- M01-RR 00052/RR/NCRR NIH HHS/United States
- R01-DK 07024/DK/NIDDK NIH HHS/United States
- R01-DK 53869/DK/NIDDK NIH HHS/United States
- R29-DK 48362/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical